Animal Drug Compounding Market By Product (Anti-infectives, Anti-inflammatory, CNS Agents), By Animal (Companion Animal, Livestock), By Dosage Form (Capsule, Solution, Powders), By Route of Administration (Oral, Injectable, Rectal)- Global Market Insights 2021 to 2031

About the Report

The global animal drug compounding market is expanding steadily with rise in demand for various animal anti-infectives and animal anti-inflammatory drugs such as tramadol, ketoconazole, and metronidazole, to name a few.

As key industry players are inventing a variety of products with different routes of administration such as oral, injectable, topical, and others, the industry is growing further in both, value and volume.

A recent report on animal drug compounding by Fact.MR offers an exhaustive overview of the global industry, along with its demand & supply patterns, major driving & restraining factors, and new trends for the forecast period of 2021 to 2031.

As stated in the report, the United States, Germany, China, India, Japan, and a few other countries will emerge lucrative markets, while 20+ other countries will have high potential during the forecast period.

Historical Vs. Future Outlook on Animal Drug Compounding

As advancements in the manufacturing and pharmaceutical sectors picked pace during the past years, animal drug compounding stakeholders have been getting highly benefitted from it. Increase in requirement for various animal drug compounding products such as CNS agents, GI drugs, veterinary anti-infectives, anti-inflammatory drugs in veterinary medicine, and others further boosted sales during the last 5 years from 2016 to 2020.

As demand for animal drug compounding products is becoming prominent, key manufacturers are focusing more on bringing in a wider variety of products with various routes of administration such as oral, injectable, topical, and ocular, to name a few. Furthermore, surge in demand from companion animal and livestock animal segments is set to aid industry growth through 2031.

How are Advancements in Pharmaceutical Sector Spearheading Demand for Animal Drug Compounding?

With advancements in the pharmaceutical sector, animal drug compounding product manufactures are coming across greater growth scope at present. According to a report published by SelectUSA on 6th September 2019, the pharmaceuticals industry is the best prospect industry in Japan.

As stated in the report, the Japan market for prescription and non-prescription pharmaceuticals in 2018 totaled US$ 87 billion in 2018, while more than 90% of the industry consists of prescription pharmaceuticals.

As per data revealed by Select USA in a report published on 30th July 2019, the Chinese pharmaceutical industry is highly potential and was valued at US$ 134 billion in 2018, and grew to approximately US$ 154 billion in 2020. These, in turn, indirectly refer to the new opportunities awaiting suppliers of compounded medication for pets around the globe.

What are the Key Challenges Faced by Veterinary Compounded Drug Manufacturers?

There are a few negative sides of animal drug compounding products and processes, such as-

• The entire process cycle is complex and time consuming
• Development of animal drug compounding products requires expensive laboratory set-ups and ingredients
• Testing and transition of animal drug compounding products often requires additional costs
• Proper testing and experts handling are required, or else, it may have adverse effects on animals

However, key players and manufactures are giving the best of their efforts in order to minimize these restraints and excel in this field.

Country-Wise Analysis

What’s Augmenting Demand for Animal Drug Compounding in the United States?

The United States has been leading in North America’s market for animal drug compounding since the past decade, and is predicted to maintain its position throughout the forecast period. Growing pharmaceutical and manufacturing sectors coupled with rise in demand for various animal drugs among people having pets are fuelling sales in the country.

According to a report titled “Pet Industry Market Size, Trends, and Ownership Statistics”, published by the American Pet Products Organization, 67% of U.S. households own pets, while in 2020, US$ 103.6 billion was spent on pets in the U.S. As stated in the report, for 2021, it is estimated that nearly US$ 109.6 billion will be spent on pets in the U.S. These represent lucrative growth scope in the U.S. for animal drug compounding product suppliers.

What’s Catering to Demand Growth for Animal Drug Compounding Products in Germany?

Germany is the leading country in Europe for animal drug compounding, and is likely to exhibit hegemony during the forecast period. Demand for various animal drug compounding products such as anti-infectives, anti-inflammatories, and others is steadily expanding, and the pharmaceutical sector is catering to demand growth in Germany.

According to a report titled “The Pharmaceutical Industry in Germany”, published by the Germany Trade & Investment (GTAI), Germany’s pharmaceutical sector generated production value of EUR 36.1 billion in 2018, making it the leading pharmaceutical manufacturing location in the European Union (EU). As stated in the report, the German pharmaceutical sector shows the highest research intensity across all major German industries, with around 12.5% of revenue being reinvested in R&D, as in 2018. This is set to create new avenues for animal drug compounding product manufacturers in the country.

What Makes China a Hotspot for Animal Drug Compounding?

China is at the forefront of Asia Pacific as far as animal drug compounding is concerned, and is anticipated to rise further through 2031. Rise in demand for various animal drug compounding products with diverse routes of administration, starting from oral to ocular, and expanding pharmaceutical sector, are spurring market growth in China.

As stated in a report titled “China- Pharmaceuticals”, published on 30th July 2019, pharmaceuticals is the best prospect industry in China. According to the report, China’s pharmaceutical industry value reached almost US$ 140 billion in 2019, and is forecast to surpass US$ 155 billion through 2031. No doubt that it will create huge opportunities for animal drug compounding stakeholders in the near future.

Why are Stakeholders Eyeing India?

India is another highly lucrative market for animal drug compounding, and is expected to grow further in the foreseeable future. Rise in demand from companion and livestock animal segments and advancements in pharmaceutical sector are propelling growth in India.

According to a report published by Invest India, India is a prominent and fast-growing pharmaceutical market, while total pharma exports is worth US$ 19.3 billion. As stated in the report, India’s pharmaceutical sector is expected to reach US$ 65 billion by 2024 and US$ 120 billion by 2030. These figures represent the high potential of India for animal drug compounding industry players.

Category-Wise Insights

Which Product is Bolstering Growth of Animal Drug Compounding?

Currently, anti-infectants are leading and are expected to sustain their position through 2031. There are various advantages of these products, such as-

• highly efficient in critical caring
• useful for preventing various infections
• has a lot of variety such as metronidazole, ketoconazole, and others
• can be administered easily

As a result, this segment sees high demand globally.

Other key segments catering to market growth are high demand for CNS agents, besides anti-inflammatory, GI drugs, and others.

Which Route of Administration is Most Preferred for Animal Drug Compounding?

Currently, oral administration is the dominant segment owing to various factors such as-

• safe
• reliable
• less side effects
• no additional cost
• hassle-free

Other key segments fueling sales in this category are injectable, topical, rectal, and ocular.

Competitive Landscape

The global animal drug compounding market offers a highly competitive environment to key players. In order to sail through the cut-throat competition, key industry players are launching more variety of products.

For instance,

• Tache Pharmacy recently launched its new range of animal drug compounding products with special flavoring, dosage adjustment, and alternative medication delivery medium.
• Smith’s Pharmacy launched its new range of animal drug compounding solutions for wound care, dermatology, postpartum care, and others, a couple of years back.

Report Scope

Market Segmentation by Category

• Product

  • Anti-Infectives
    • Metronidazole
    • Ketoconazole
    • Other Antibiotics
  • Anti-Inflammatory
    • Prednisolone
    • Tramadol
    • Other Anti-Inflammatory
  • CNS Agents
    • Potassium Bromide
    • Gabapentin
    • Other CNS Agents
  • GI Drugs
    • Apomorphine
    • Ursodiol
    • Cisapride
    • Other GI Drugs
  • Others
    • Methimazole
    • Other Drugs

• Route of Administration

  • Oral Animal Drug Compounding
  • Injectable Animal Drug Compounding
  • Topical Animal Drug Compounding
  • Rectal Animal Drug Compounding
  • Ocular Animal Drug Compounding

• Animal Type

  • Companion Animal
    • Animal Drug Compounding for Dogs
    • Animal Drug Compounding for Cats
    • Animal Drug Compounding for Horses
    • Animal Drug Compounding for Birds
    • Others
  • Livestock Animal

• Dosage Form

  • Animal Drug Compounding Capsules
  • Animal Drug Compounding Suspension
  • Animal Drug Compounding Solutions
  • Animal Drug Compounding Powders
  • Others

• Region

  • North America
  • Latin America
  • Europe
  • Middle East and Africa (MEA)
  • East Asia
  • South Asia
  • Oceania